Literature DB >> 8239583

Penetration of foscarnet into cerebrospinal fluid of AIDS patients.

F Raffi1, A M Taburet, B Ghaleh, A Huart, E Singlas.   

Abstract

The diffusion of foscarnet into cerebrospinal fluid (CSF) was studied in 27 patients with AIDS. Foscarnet was administered intravenously at various dosages at 12-h intervals. Concentrations in plasma and CSF at the end of foscarnet infusion or 1, 3, 5, 6, and 12 h after infusion were determined by high-performance liquid chromatography. Thirty-seven samples were obtained. The median concentration of foscarnet in CSF was 80 mumol/liter (range, 0 to 500 mumol/liter). The CSF foscarnet concentration was greater than the 50% inhibitory concentration for human immunodeficiency virus type 1 and was equal to or greater than the 50% inhibitory concentration for cytomegalovirus in most cases. The penetration of foscarnet into CSF, as expressed by the ratio of the concentration in CSF to the simultaneous concentration in plasma, ranged from 0 to 3.4 (median, 0.27) and was highly correlated with the presence of cells within CSF and the length of foscarnet therapy. Good diffusion of foscarnet in CSF allows evaluation of this drug in central nervous system cytomegalovirus and human immunodeficiency virus infections in patients with AIDS.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8239583      PMCID: PMC188069          DOI: 10.1128/AAC.37.9.1777

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  Pharmacokinetics of foscarnet after twice-daily administrations for treatment of cytomegalovirus disease in AIDS patients.

Authors:  A M Taburet; C Katlama; C Blanshard; G Zorza; D Gazzard; E Dohin; B G Gazzard; C Frostegard; E Singlas
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

2.  Inhibition of HTLV-III/LAV replication by foscarnet.

Authors:  P S Sarin; Y Taguchi; D Sun; A Thornton; R C Gallo; B Oberg
Journal:  Biochem Pharmacol       Date:  1985-11-15       Impact factor: 5.858

3.  Inhibition of human T-cell lymphotropic virus type III in vitro by phosphonoformate.

Authors:  E G Sandstrom; J C Kaplan; R E Byington; M S Hirsch
Journal:  Lancet       Date:  1985-06-29       Impact factor: 79.321

Review 4.  Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis.

Authors:  P Chrisp; S P Clissold
Journal:  Drugs       Date:  1991-01       Impact factor: 9.546

5.  Combinations of 3'-azido-3'-deoxythymidine (zidovudine) and phosphonoformate (foscarnet) against human immunodeficiency virus type 1 and cytomegalovirus replication in vitro.

Authors:  B F Eriksson; R F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191

Review 6.  Antiviral effects of phosphonoformate (PFA, foscarnet sodium).

Authors:  B Oberg
Journal:  Pharmacol Ther       Date:  1989       Impact factor: 12.310

7.  Reversible inhibition of cytomegalovirus replication by phosphonoformate.

Authors:  B Wahren; B Oberg
Journal:  Intervirology       Date:  1980       Impact factor: 1.763

Review 8.  Clinical pharmacology: foscarnet.

Authors:  P S Lietman
Journal:  Am J Med       Date:  1992-02-14       Impact factor: 4.965

9.  In vivo additive antiretroviral effect of combined zidovudine and foscarnet therapy for human immunodeficiency virus infection (ACTG Protocol 053).

Authors:  M A Jacobsen; C van der Horst; D M Causey; M Dehlinger; R Hafner; J Mills
Journal:  J Infect Dis       Date:  1991-06       Impact factor: 5.226

10.  Determination of phosphonoformate (foscarnet) in biological fluids by ion-pair reversed-phase liquid chromatography.

Authors:  K J Pettersson; T Nordgren; D Westerlund
Journal:  J Chromatogr       Date:  1989-03-24
View more
  9 in total

1.  Intravitreal, retinal, and central nervous system foscarnet concentrations after rapid intravenous administration to rabbits.

Authors:  L F López-Cortés; R Ruiz-Valderas; M J Lucero-Muñoz; E Cordero; M T Pastor-Ramos; J Marquez
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

2.  A fatal case of cytomegalovirus ventriculoencephalitis in a mycosis fungoides patient who received multiple umbilical cord blood cell transplantations.

Authors:  Toshihiro Matsukawa; Hideki Goto; Kenta Takahashi; Shinsuke Asanuma; Atsushi Yasumoto; Mutsumi Takahata; Akio Shigematsu; Tomoyuki Endo; Junji Tanaka; Satoshi Hashino; Shinya Tanaka; Masahiro Imamura
Journal:  Int J Hematol       Date:  2012-01-20       Impact factor: 2.490

3.  Clinical characteristics and outcome of human herpesvirus-6 encephalitis after allogeneic hematopoietic stem cell transplantation.

Authors:  M Ogata; K Oshima; T Ikebe; K Takano; H Kanamori; T Kondo; Y Ueda; T Mori; H Hashimoto; H Ogawa; T Eto; T Ueki; T Miyamoto; T Ichinohe; Y Atsuta; T Fukuda
Journal:  Bone Marrow Transplant       Date:  2017-08-07       Impact factor: 5.483

4.  Overton's rule helps to estimate the penetration of anti-infectives into patients' cerebrospinal fluid.

Authors:  Marija Djukic; Martin Munz; Fritz Sörgel; Ulrike Holzgrabe; Helmut Eiffert; Roland Nau
Journal:  Antimicrob Agents Chemother       Date:  2011-11-21       Impact factor: 5.191

5.  Relevance of clinical and laboratory findings in the diagnosis of cytomegalovirus encephalitis in patients with AIDS.

Authors:  C Mussini; N Mongiardo; G Manicardi; F Trenti; A Alessandrì; F Paolillo; A Catania; M Portolani; M Pecorari; V Borghi; G Ficarra; A Cossarizza; B De Rienzo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-06       Impact factor: 3.267

Review 6.  Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections.

Authors:  Roland Nau; Fritz Sörgel; Helmut Eiffert
Journal:  Clin Microbiol Rev       Date:  2010-10       Impact factor: 26.132

Review 7.  Human herpesvirus-6 encephalitis after allogeneic hematopoietic cell transplantation: what we do and do not know.

Authors:  M Ogata; T Fukuda; T Teshima
Journal:  Bone Marrow Transplant       Date:  2015-04-27       Impact factor: 5.483

Review 8.  Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections.

Authors:  A J Wagstaff; H M Bryson
Journal:  Drugs       Date:  1994-08       Impact factor: 9.546

Review 9.  Current pharmacological approaches to the therapy of varicella zoster virus infections: a guide to treatment.

Authors:  R Snoeck; G Andrei; E De Clercq
Journal:  Drugs       Date:  1999-02       Impact factor: 11.431

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.